1. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

ADC Toxin

" in MedChemExpress (MCE) Product Catalog:

99

Inhibitors & Agonists

5

Fluorescent Dye

1

Biochemical Assay Reagents

1

Peptides

2

Inhibitory Antibodies

8

Natural
Products

3

Isotope-Labeled Compounds

1

Click Chemistry

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-138298A
    Trastuzumab deruxtecan
    5 Publications Verification

    T-DXd; DS-8201; DS-8201a

    Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
    Trastuzumab deruxtecan
  • HY-138298
    Trastuzumab deruxtecan (solution)
    5 Publications Verification

    T-DXd (solution); DS-8201 (solution); DS-8201a (solution)

    Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
    Trastuzumab deruxtecan (solution)
  • HY-16700

    ADC Payload Topoisomerase Cancer
    PNU-159682, a metabolite of the anthracycline Nemorubicin, is a highly potent DNA topoisomerase II inhibitor with excellent cytotoxicity. PNU-159682 acts as a more potent and tolerated ADC cytotoxin than Doxorubicin for ADC synthesis. PNU-159682 can be used in EDV-nanocell technology to overcome agent resistance.
    PNU-159682
  • HY-132162

    ADC Payload Cancer
    7-MAD-MDCPT, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs) .
    7-MAD-MDCPT
  • HY-128915

    DNA Alkylator/Crosslinker ADC Payload Cancer
    Duocarmycin DM free base, a DNA minor-groove alkylator, is an antibody agent conjugates (ADCs) toxin. Duocarmycin DM free base is based on its characteristic curved indole structure and a spirocyclopropylcyclohexadienone electrophile to act anticancer activity .
    Duocarmycin DM free base
  • HY-164702

    Izalontamab Brengitecan

    Antibody-Drug Conjugates (ADCs) EGFR Cancer
    BL-B01D1 is a bispecific ADC, which targets EGFR and HER3 through bispecific antibody Izalontamab (HY-P99676), and exhibits cytotoxicity against various cancer cells via inhibition of DNA replication and DNA synthesis by its ADC toxin ED04 (HY-153891). BL-B01D1 can be used in the study of cancer .
    BL-B01D1
  • HY-125586

    DNA/RNA Synthesis ADC Payload Cancer
    β-Amanitin is a cyclic peptide toxin in the poisonous Amanita phalloides mushroom. β-Amanitin inhibits inhibits eukaryotic RNA polymerase II and III. β-Amanitin inhibits protein synthesis. β-Amanitin can be used as a cytotoxic component of antibody-drug conjugates (ADCs) .
    β-Amanitin
  • HY-147340

    Tirumotecan

    Drug-Linker Conjugates for ADC Cancer
    TL033 is a drug-Linker conjugates for ADC. TL033 contains a linker and bioactive small molecule toxins. TL033 can conjugate with Sacituzumab antibody (anti Trop-2) for synthesizing BT001021. BT001021 has anti-cancer activities against various cancers, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer .
    TL033
  • HY-147340A

    Tirumotecan TFA

    Drug-Linker Conjugates for ADC Cancer
    TL033 TFA is a drug-Linker conjugates for ADC. TL033 TFA contains a linker and bioactive small molecule toxins. TL033 TFA can conjugate with Sacituzumab antibody (anti Trop-2) for synthesizing BT001021. BT001021 has anti-cancer activities against various cancers, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer .
    TL033 TFA
  • HY-131089

    DNA/RNA Synthesis Drug-Linker Conjugates for ADC Cancer
    MC-VC-PABC-C6-α-Amanitin is a Drug-Linker Conjugates for ADC, consisting of an anticancer toxin alpha-Amanitin (HY-19610) and a MC-VC-PABC-C6 linker. Among them, alpha-Amanitin is a potent inhibitor of RNA polymerase IIα.
    MC-VC-PABC-C6-α-Amanitin
  • HY-164285

    IMP1320

    ADC Payload N-myristoyltransferase Cancer
    MYX1715 is an inhibitor of N-Myristoyltransferase (NMT) with a KD value of 0.09 nM. MYX1715 inhibits the proliferation of LU0884 and LU2511 with IC50 values of 44 nM and 9 nM. MYX1715 exhibits antitumor efficacy against neuroblastoma and gastric cancer in mouse models. MYX1715 can be used as ADC toxin .
    MYX1715
  • HY-153069

    Drug-Linker Conjugates for ADC Topoisomerase Cancer
    GGFG-PAB-Exatecan consists of an ADC toxin Exatecan (HY-13631) and a linker GGFG-PAB, and can be used as a drug-linker conjugate for the synthesis of ADC molecules .
    GGFG-PAB-Exatecan
  • HY-79490

    ADC Payload Topoisomerase Cancer
    Ac-Exatecan is acetylation-modified Exatecan (HY-13631). Exatecan is a common toxin component in ADC preparation (ADC cytotoxin) and an inhibitor of DNA topoisomerase I (IC50 = 2.2 μM). Exatecan has antitumor activity. Exatecan can be used as a payload for ADC. Exatecan is effective against P-glycoprotein mediated multi-drug resistant cells .
    Ac-Exatecan
  • HY-159072

    Drug-Linker Conjugates for ADC Cancer
    Mal-Val-Ala-PAB-N(SO2Me)-Exatecan (Compound LE14) is a conjugate of an ADC toxin Exatecan (HY-13631) and a linker Mal-Val-Ala-PAB-N(SO2Me). Mal-Val-Ala-PAB-N(SO2Me)-Exatecan can be used for synthesis of ADC FZ-AD005. FZ-AD005 is a delta-like ligand 3 (DLL3, KD=58.3 pM) targeting ADC, that exhibits antitumor efficacy against SCLC cancer .
    Mal-Val-Ala-PAB-N(SO2Me)-Exatecan
  • HY-43565

    ADC Payload Topoisomerase Cancer
    Exatecan intermediate 9 is an intermediate for the synthesis of Exatecan (HY-13631). Exatecan (DX-8951) is a common toxin component in ADC preparation (ADC Cytotoxin) and an inhibitor of DNA topoisomerase I (IC50=2.2 μM) .
    Exatecan intermediate 9
  • HY-N7053

    ADC Payload Microtubule/Tubulin Cancer
    Tubulysin M is a highly cytotoxic anti-microtubule toxin (anti-microtubule toxins) that is synthesized as an ADC cytotoxin (ADC Cytotoxin). Tubulysin M can be isolated from the myxobacteria Archangium geophyra and Angiococcus disciformis. Tubulysin M displays extremely potent cytotoxic activity in mammalian cells, including multidrug-resistant cell lines, with IC50 values in the low nanomolar range. Tubulysin M inhibits microtubule/tubulin polymerization and leads to cell cycle arrest and apoptosis .
    Tubulysin M
  • HY-15581

    Demethyldolastatin 10; Monomethylauristatin D; Monomethyl Dolastatin 10

    Microtubule/Tubulin ADC Payload Cancer
    MMAD is a potent tubulin inhibitor, is a toxin payload in antibody agent conjugates (ADCs).
    MMAD
  • HY-W591408

    Drug-Linker Conjugates for ADC Cancer
    DBCO-Val-Cit-PAB-MMAE is a drug-linker conjugate, which can be used for the synthesis of ADC molecules. MMAE (HY-15162) is a tubulin inhibitor, which can be used as an ADC toxin. DBCO-Val-Cit-PAB is the linker with the electrophilic group .
    DBCO-Val-Cit-PAB-MMAE
  • HY-160807

    Drug-Linker Conjugates for ADC Cancer
    DBM-GGFG-NH-O-CO-Exatecan (Example 4, Compound 14) is a conjugate of an ADC drug toxin molecule and a linker. DBM-GGFG-NH-O-CO-Exatecan is a complete antibody-drug conjugate intermediate that integrates a potent camptothecin-based toxin, a cleavable peptide linker (GGFG), and a reactive terminus that can directly conjugate to antibodies .
    DBM-GGFG-NH-O-CO-Exatecan
  • HY-128873

    ADC Payload DNA Alkylator/Crosslinker Cancer
    Duocarmycin GA is an antibody agent conjugates (ADCs) toxin. Duocarmycin is a DNA alkylating agent that binds in the minor groove. Duocarmycin GA can be used against multi-agent resistant cell lines.
    Duocarmycin GA
  • HY-145622

    BA3011; CAB-Axl-ADC; CAB-anti-Axl-ADC

    Antibody-Drug Conjugates (ADCs) TAM Receptor Cancer
    Mecbotamab vedotin (BA3011) is a pH dependent antibody drug conjugate (ADC) targeting AXL. Mecbotamab vedotin can significantly inhibit AXL in DU145 cells and LCLC-103H cells and kills cells. Mecbotamab vedotin can be used for research on cancer such as lung cancer, pancreatic cancer and prostate cancer. The antibody component is Mecbotamab (HY-P9988), and the ADC toxin molecule is Monomethyl auristatin E (MMAE) (HY-15162) .
    Mecbotamab vedotin
  • HY-132180

    ADC Payload Inflammation/Immunology Cancer
    Seco-DUBA hydrochloride is a toxin for ADC drug SYD985 .
    Seco-DUBA hydrochloride
  • HY-132162A

    ADC Payload Cancer
    7-MAD-MDCPT hydrochloride, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs) .
    7-MAD-MDCPT hydrochloride
  • HY-130978

    DNA Alkylator/Crosslinker ADC Payload Cancer
    Duocarmycin DM, a DNA minor-groove alkylator, is an antibody agent conjugates (ADCs) toxin. Duocarmycin DM is based on its characteristic curved indole structure and a spirocyclopropylcyclohexadienone electrophile to act anticancer activity .
    Duocarmycin DM
  • HY-164088

    Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    DBM-C5-VC-PAB-MMAE (Compound 3a) is a Drug-Linker conjugate for ADC. DBM-C5-VC-PAB-MMAE is composed of a linker C5-VC-PAB with a maleimide group DBM and an ADC toxin MMAE (HY-15162) .
    DBM-C5-VC-PAB-MMAE
  • HY-78932A

    ADC Linker Cancer
    Dap-NE hydrochloride is a dipeptide hydrochloride and a cleavable ADC Linker.Dap-NE hydrochloride can be used to connect Antibody and toxin molecules (Cytotoxin) to synthesize Antibody-Drug Conjugates (ADCs) .
    Dap-NE hydrochloride
  • HY-N2348

    ADC Payload Microtubule/Tubulin Cancer
    Tubulysin D is a highly cytotoxic anti-microtubule toxin (anti-microtubule toxins) that is synthesized as an ADC cytotoxin (ADC Cytotoxin). Tubulysin D can be isolated from the myxobacteria Archangium geophyra and Angiococcus disciformis. Tubulysin D displays extremely potent cytotoxic activity in mammalian cells, including multidrug-resistant cell lines, with IC50 values in the low nanomolar range. Tubulysin D inhibits microtubule/Tubulin polymerization and leads to cell cycle arrest and apoptosis .
    Tubulysin D
  • HY-168317

    Drug-Linker Conjugates for ADC Cancer
    LNK2-S is a conjugated compound of toxin molecule Exatecan (HY-13631) and Linker, which can be used to synthesize ADC molecule .
    LNK2-S
  • HY-41047

    Apoptosis Cancer
    Taltobulin intermediate-1 is an intermediate in the synthesis of Taltobulin (HY-15584). Taltobulin is a common toxin component in ADC preparation (ADC Cytotoxin), and it is also a powerful tubulin (Microtubule/Tubulin) inhibitor. Taltobulin disrupts tubulin polymerization, induces mitotic arrest, and induces apoptosis .
    Taltobulin intermediate-1
  • HY-41054

    Apoptosis Cancer
    Taltobulin intermediate-3 is an intermediate in the synthesis of Taltobulin (HY-15584). Taltobulin is a common toxin component in ADC preparation (ADC Cytotoxin), and it is also a powerful tubulin (Microtubule/Tubulin) inhibitor. Taltobulin disrupts tubulin polymerization, induces mitotic arrest, and induces apoptosis .
    Taltobulin intermediate-3
  • HY-41045

    Apoptosis Cancer
    (Rac)-Taltobulin intermediate-1 is an intermediate in the synthesis of Taltobulin (HY-15584). Taltobulin is a common toxin component in ADC preparation (ADC Cytotoxin), and it is also a powerful tubulin (Microtubule/Tubulin) inhibitor. Taltobulin disrupts tubulin polymerization, induces mitotic arrest, and induces apoptosis .
    (Rac)-Taltobulin intermediate-1
  • HY-111965

    anti-EFNA4-ADC

    Antibody-Drug Conjugates (ADCs) DNA Alkylator/Crosslinker Antibiotic Apoptosis Cancer
    PF-06647263 is an ADC targeting EFNA4, consisting of EFNA4 Antibody (HY-P991109), ADC toxin Calicheamicin (HY-19609) and a linker. PF-06647263 exhibits anti-tumor activity and induces significant tumor regression in TNBC xenografts .
    PF-06647263
  • HY-171489

    Drug-Linker Conjugates for ADC Cancer
    Mal-VC-PAB-EDA-N-Ac-Calicheamicin is a Drug-Linker Conjugate for ADC with potent antitumor activity. Mal-VC-PAB-EDA-N-Ac-Calicheamicin consists of ADC toxin Calicheamicin (HY-19609) and a linker. Mal-VC-PAB-EDA-N-Ac-Calicheamicin can be used for synthesis of ADC, PF-06647263 (HY-111965) .
    Mal-VC-PAB-EDA-N-Ac-Calicheamicin
  • HY-148380

    Drug-Linker Conjugates for ADC Topoisomerase Cancer
    Mal-PEG8-Phe-Lys-PAB-Exatecan (compound 15) is a agent-linker conjugate for ADC, composed of degradable linker Mal-PEG8-Phe-Lys-PAB and toxin molecule Exatecan (HY-13631) composition .
    Mal-PEG8-Phe-Lys-PAB-Exatecan
  • HY-170406

    Bcl-2 Family Cancer
    BCL-XL-IN-3 (Compound 11) is an inhibitor for BCL-XL with a Ki < 0.01 nM. BCL-XL-IN-3 inhibits the cell viability in normal Molt-4 and Digitonin (HY-N4000)-permeabilized Molt-4 with EC50 of 77.8 nM and 0.07 nM. BCL-XL-IN-3 can be used as ADC toxin for synthesis of Clezutoclax (HY-137774) .
    BCL-XL-IN-3
  • HY-178219

    Drug-Linker Conjugates for ADC Microtubule/Tubulin Apoptosis Cancer
    Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE contains a linker and bioactive small molecule toxins MMAE (HY-15162). Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE can conjugate with NN2101 (HY-P991293) (anti c-Kit) for synthesizing NN3201. NN3201 rapidly internalizes and inhibits SCF-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models, such as small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST) .
    Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE
  • HY-122306

    Mycotrienin II

    Antibiotic Bacterial Infection Cancer
    Ansatrienin B (Mycotrienin II) is an ansamycin antibiotic isolated from Streptomyces. Ansatrienin B is active against fungi and yeasts, but inactive against bacteria.Ansatrienin B displays antitumor antibiotic activity and can be used as an ADC Toxin .
    Ansatrienin B
  • HY-45171

    ADC Payload Cancer
    Exatecan intermediate 12 is an intermediate for the synthesis of ADC toxin Exatecan (HY-13631) and can be used to prepare ADC compounds .
    Exatecan intermediate 12
  • HY-N2347

    ADC Payload Microtubule/Tubulin Cancer
    Tubulysin C is a highly cytotoxic anti-microtubule toxin (anti-microtubule toxins) that is synthesized as an ADC cytotoxin (ADC Cytotoxin). Tubulysin C can be isolated from the myxobacteria Archangium geophyra and Angiococcus disciformis. Tubulysin C displays extremely potent cytotoxic activity in mammalian cells, including multidrug-resistant cell lines, with IC50 values in the low nanomolar range. Tubulysin C inhibits microtubule/Tubulin polymerization and leads to cell cycle arrest and apoptosis .
    Tubulysin C
  • HY-N7050

    ADC Payload Microtubule/Tubulin Cancer
    Tubulysin G is a highly cytotoxic anti-microtubule toxin (anti-microtubule toxins) that is synthesized as an ADC cytotoxin (ADC Cytotoxin). Tubulysin G can be isolated from the myxobacteria Archangium geophyra and Angiococcus disciformis. Tubulysin G displays extremely potent cytotoxic activity in mammalian cells, including multidrug-resistant cell lines, with IC50 values in the low nanomolar range. Tubulysin G inhibits microtubule/tubulin polymerization and leads to cell cycle arrest and apoptosis .
    Tubulysin G
  • HY-N7052

    ADC Payload Microtubule/Tubulin Cancer
    Tubulysin I is a highly cytotoxic anti-microtubule toxin (anti-microtubule toxins) that is synthesized as an ADC cytotoxin (ADC Cytotoxin). Tubulysin I can be isolated from the myxobacteria Archangium geophyra and Angiococcus disciformis. Tubulysin I displays extremely potent cytotoxic activity in mammalian cells, including multidrug-resistant cell lines, with IC50 values in the low nanomolar range. Tubulysin I inhibits microtubule/tubulin polymerization and leads to cell cycle arrest and apoptosis .
    Tubulysin I
  • HY-107770

    ADC Payload DNA Alkylator/Crosslinker Cancer
    Duocarmycin MB is an antibody agent conjugates (ADCs) toxin. Duocarmycin is a DNA alkylating agent that binds in the minor groove. Duocarmycin MB can be used against multi-agent resistant cell lines.
    Duocarmycin MB
  • HY-18987

    ADC Payload DNA Alkylator/Crosslinker Cancer
    Duocarmycin MA is an antibody agent conjugates (ADCs) toxin. Duocarmycin is a DNA alkylating agent that binds in the minor groove. Duocarmycin MA can be used against multi-agent resistant cell lines.
    Duocarmycin MA
  • HY-164303

    Drug-Linker Conjugates for ADC DNA Alkylator/Crosslinker Cancer
    Val-Cit-PAB-DEA-Duo-DM is a drug-linker conjugate, which consists of the linker Val-Cit-PAB, the spacer DEA and the ADC toxin Duocarmycin DM (Duo-DM) (HY-130978). Val-Cit-PAB-DEA-Duo-DM can be used for the synthesis of ADC molecule .
    Val-Cit-PAB-DEA-Duo-DM
  • HY-148380A

    Drug-Linker Conjugates for ADC Topoisomerase Cancer
    Mal-PEG8-Phe-Lys-PAB-Exatecan TFA is a agent-linker conjugate for ADC, composed of degradable linker Mal-PEG8-Phe-Lys-PAB and toxin molecule Exatecan (HY-13631) .
    Mal-PEG8-Phe-Lys-PAB-Exatecan TFA
  • HY-133570

    HSP ADC Payload Cancer
    17-AEP-GA, an HSP90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion. ADCs Toxin .
    17-AEP-GA
  • HY-128979B

    Drug-Linker Conjugates for ADC Cancer
    Deruxtecan analog 2 (monoTFA) is a homolog of Deruxtecan (HY-13631E), a conjugate of the ADC toxin DX-8951 derivative (Dxd) with an ADC Linker .
    Deruxtecan analog 2 monoTFA
  • HY-153069A

    Topoisomerase Drug-Linker Conjugates for ADC Cancer
    GGFG-PAB-Exatecan TFA consists of an ADC toxin Exatecan (HY-13631) and a linker GGFG-PAB, and can be used as a drug-linker conjugate for the synthesis of ADC molecules .
    GGFG-PAB-Exatecan TFA
  • HY-78932

    ADC Payload Cancer
    Dap-NE is an intermediate reagent in the synthesis of the ADC toxin Monomethyl auristatin E (HY-15162) .
    Dap-NE
  • HY-132162B

    ADC Payload Cancer
    7-MAD-MDCPT TFA, a Camptothecin analog, is a toxin payload in antibody drug conjugates (ADCs) .
    7-MAD-MDCPT TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: